Compared to the PCOS group, the levels of p-Smad3 significantly decreased (P < 0.01), while the levels of Smad7 were dramatically increased (P < 0.01) in the Rha-treated group and the Met-treated group. The gene discussed is SMAD3; the disease is polycystic ovary syndrome.